Metanx® is a prescription product indicated for the dietary management of homocysteine and endothelial dysfunction with particular emphasis in patients with diabetic peripheral neuropathy (DPN).

Each Metanx® tablet contains:

L-methylfolate 2.8mg
Pyridoxal 5'-phosphate 25mg
Methylcobalamin 2mg

How Does Metanx® Work?
Every complication that develops in diabetes is related to circulatory disease, and nitric oxide plays a significant role in that process.

Lack of protective sensation is the number one predictor of lower-extremity ulcerations and amputation.

Elevated homocysteine is a significant risk factor for impaired wound healing in patients with chronic lower extremity ulcerations.

The majority of painful DPN symptoms include numbness and tingling due to lack of sensation. Only 10-25% of patients with DPN experience painful symptoms. Current DPN therapies only target the painful symptoms while the underlying disease state progresses.

For more information on Metanx® and Diabetic Peripheral Neuropathy, click here.

For more information on Metanx® and Lower Extremity Ulcerations, click here.

To receive further information or free Metanx® samples, click here.

A medical food for the dietary management of endothelial dysfunction and/or hyperhomocysteinemia.

  1. Stroes ESC, et al. Folic Acid Reverts Dysfunction of Endothelial Nitric Oxide Synthase. Circulation Research. 2000;86:1129-1134.
  2. Vascular Disease Mangagement 2005;2 (Suppl 6):1S-9S.
  3. Boykin JV, Baylis C. Homocysteine--A Stealth Mediator of Impaired Wound Healing: A Preliminary Study. Wounds 2006;18(4):101-116.
  4. Yaqub, Basim A, et al. Effects of methylcobalamin on diabetic neuropathy. Clinical Neurology and Neurosurgery 1992;94:105-111.
  5. Devathasan G, et al. Methylcobalamin (CH3-B12;Methycobal) in Chronic Diabetic Neuropathy: A Double-Blind Clinical and Electrophysiological Study. Clinical Trials Journal 1986;23(2):130-140.